On the Record · Icon
Icon acquisitions, on the record
The businesses Icon bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
BioTel Research, LLC (formerly Philips Pharma Solutions)Word for word“On October 2, 2023, the Company acquired 100% of the equity of BioTel Research, LLC which comprised the business formerly known as Philips Pharma Solutions, a leading provider of medical imaging and cardiac safety monitoring services.” 20-F for 2023 | acquisition | On October 2, 2023 | — |
Oncacare LimitedWord for word“On April 20, 2023, the Company completed the purchase of the majority investor's 51% voting share capital of Oncacare Limited ( such that Oncacare and its subsidiaries became wholly-owned subsidiaries of the ICON Group) , a global network of oncology research sites that provide a unique patient recruitment and delivery solution for the clinical research industry.” 20-F for 2023 | acquisition | On April 20, 2023 | — |
PRA Health Sciences, Inc.Word for word“The total value of the Merger consideration was $12.0 billion and has resulted in the recognition of goodwill of $8.1 billion, intangible assets of $4.9 billion and an associated deferred tax liability of $1.1 billion.” 20-F for 2023 | acquisition | — | $12.0 billion |
KCR S.A Group ("KCR")Word for word“On August 19, 2024, the Company acquired the KCR S.A Group ("KCR"), a CRO offering full service and functional services partnership ("FSP") clinical trial services.” 20-F for 2024 | acquisition | On August 19, 2024 | — |
HumanFirst, Inc. ("HumanFirst")Word for word“On January 9, 2024, the Company acquired HumanFirst, Inc. ("HumanFirst"), a life sciences technology company.” 20-F for 2024 | acquisition | On January 9, 2024 | — |
BioTel Research, LLC which comprised the business formerly known as Philips Pharma SolutionsWord for word“On October 2, 2023, the Company acquired 100% of the equity of BioTel Research, LLC which comprised the business formerly known as Philips Pharma Solutions, a leading provider of medical imaging and cardiac safety monitoring services.” 20-F for 2024 | acquisition | On October 2, 2023 | — |
Oncacare Limited (51% voting share capital)Word for word“On April 20, 2023, the Company completed the purchase of the majority investor's 51% voting share capital of Oncacare Limited (such that Oncacare and its subsidiaries became wholly-owned subsidiaries of the ICON Group), a global network of oncology research sites that provide a unique patient recruitment and delivery solution for the clinical research industry.” 20-F for 2024 | acquisition | On April 20, 2023 | — |
KCR S.A GroupWord for word“On August 19, 2024, the Company acquired the KCR S.A Group (“KCR”), a CRO offering full service and functional services provision (‘FSP’) clinical trial services.” 20-F for 2025 | acquisition | August 19, 2024 | — |
HumanFirst, Inc.Word for word“On January 9, 2024, the Company acquired HumanFirst, Inc. (“HumanFirst”), a life sciences technology company.” 20-F for 2025 | acquisition | January 9, 2024 | — |
BioTel Research, LLCWord for word“On October 2, 2023, the Company acquired 100% of the equity of BioTel Research, LLC which comprised the business formerly known as Philips Pharma Solutions, a leading provider of medical imaging and cardiac safety monitoring services.” 20-F for 2025 | acquisition | October 2, 2023 | — |
Symphony Health Solutions CorporationWord for word“On May 8, 2026, ICON completed the disposition of Symphony Health Solutions Corporation ("Symphony") pursuant to a merger agreement, by and among HealthVerity, Inc. ("HealthVerity"), Symphony, Pharmaceutical Research Associates, Inc. and HealthVerity Merger Sub, Inc. ("HV Merger Sub"), a wholly owned subsidiary of HealthVerity.” 20-F for 2025 | divestiture | May 8, 2026 | — |
PRA Health Sciences, Inc.Word for word“On July 1, 2021, the Company completed the acquisition of PRA by means of a merger whereby Indigo Merger Sub, Inc., a Delaware corporation and subsidiary of ICON, merged with and into PRA Health Sciences, Inc., the parent of PRA Health Sciences (the “Acquisition” and the “Merger”).” 20-F for 2025 | merger | July 1, 2021 | — |
| Fiscal year ended | Goodwill from acquisitions |
|---|---|
| 2016-12-31 | $34.6 million |
| 2017-12-31 | $129.2 million |
| 2018-12-31 | $0 |
| 2019-12-31 | $126.9 million |
| 2020-12-31 | $27.2 million |
| 2021-12-31 | $8.12 billion |
| 2022-12-31 | $0 |
| 2023-12-31 | $36.8 million |
| 2024-12-31 | $46.1 million |
| 2025-12-31 | $0 |
Read from Icon’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-05-27. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.